Carmustine
From Wikipedia, the free encyclopedia
![]() |
|
Carmustine
|
|
Systematic (IUPAC) name | |
1,3-bis(2-chloroethyl)-1-nitroso-urea | |
Identifiers | |
CAS number | |
ATC code | L01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C5H9Cl2N3O2 |
Mol. mass | 214.049 g/mol |
Pharmacokinetic data | |
Bioavailability | 5 to 28% (oral) |
Protein binding | 80% |
Metabolism | Hepatic (CYP1A2-mediated) |
Half life | 15 to 30 minutes |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status |
℞ Prescription only |
Routes | Intravenous, wafer for implant |
Carmustine or BCNU is a mustard gas-related β-chloro-nitrosourea compound used as an alkylating agent in chemotherapy. It is used in the treatment of several types of brain cancer (including glioma, glioblastoma multiforme, medulloblastoma and astrocytoma), multiple myeloma and lymphoma (Hodgkin's and non-Hodgkin). Carmustine for injection is marketed under the name BiCNU® by Bristol-Myers Squibb.
Bone marrow may take 6 weeks to recover function following treatment with carmustine. Weekly monitoring of platelet and white blood cell counts are recommended as a basis for patient-specific adjustments to dosage regimens. Bone marrow and pulmonary toxicities are a function of lifetime cumulative dose.
[edit] External links
- MedlinePlus DrugInfo medmaster-a682060
- BiCNU® (package insert; U.S.)